Does anyone follow MCU - Medicure? Your opinion please?
Based on my last meeting with Burt Friesen I do not believe that a partnership will be signed in the immediate future. Many investors want to see a partner to validate the technology. That way they can trade out of the stock on the news. The fact that I don’t think there will be a partner removes one of the catalysts that I was looking for. It appears that I will have to be content with what I believe will be growing sales of the already approved product, Aggrastat, and the completion of the trial of MC-1 in CABG surgery. In the phase 2 trial of MC-1 the drug had a reduction of myocardial infarction, stroke and death of 37 percent with a p-value of .028. That is very statistically and clinically significant. If you remove stroke, endpoint results improve dramatically. Non-fatal myocardial infarctions and death were reduced by 43 percent with a p-value of .009. The FDA has agreed to remove stroke, as an endpoint. Stroke will only be followed as an adverse event where it belongs. The company included stroke as one of the endpoints in the phase 2 trial because the mechanism of action of the drug should actually reduce the severity of a stroke. The drug would not prevent stroke, so they miscalculated by including it in the endpoint. That is what phase 2 trials are for. The amazing thing in the case of Medicure is that most phase 2’s are used to determine what you need to do to get a positive phase 3 result. In Medicure’s case, the FDA has accepted the phase 2 trial as a pivotal study. Medicure only needs to complete one phase 3-trial. This is very unusual indeed.
Of course there are others on the board that think the drug doesn't work. I have been doing this long enough. I make my own decisions
